Background: Studies at the population level have demonstrated associations between pemphigus (pemphigus vulgaris, PV, and pemphigus foliaceus, PF) and particular HLA haplotypes, which suggests that there may be a genetic predisposition for the disease. Objective/Methods: The aim of the present study was to examine the distribution/frequency pattern of HLA class II alleles (DRB1, DQA1 and DQB1) from a group of 30 Korean patients with pemphigus (15 PV and 15 PF) by PCR amplification with sequence-specific primers. Results: In PV, the frequency of DRB1*01 allele was found to be significantly high (pc = 0.0014); in PF, DRB1*01, DQA1*0302 and DQB1*0603 alleles showed positive associations with statistical significances (pc = 0.0002, 0.0007 and 0.0067, respectively), when compared with those found in Korean controls. Conclusions: In this small-sample study, findings of allelic frequencies among Korean patients with pemphigus are somewhat different from those found in other populations.

Keywords:
Pemphigus vulgaris, Pemphigus foliaceus, HLA class II allele
1.
Stanley JR: Autoantibodies against adhesion molecules and structures in blistering skin diseases. J Exp Med 1995;181:1–4.
2.
Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92: 11935–11939.
3.
Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, Yunis EJ: Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 1991;88: 5056–5060.
4.
Lombardi ML, Mercuro O, Tecame C, Fusco C, Ruocco V, Salerno A, Pirozzi G, Manzo C: Molecular analysis of HLA DRB1 and DQB1 in Italian patients with pemphigus vulgaris. Tissue Antigen 1996;47:228–230.
5.
Cerna M, Fernandez-Vina M, Friedman H, Moraes JR, Moraes ME, Diaz L, Stastny P: Genetic markers for susceptibility to endemic Brazilian pemphigus foliaceus (fogo selvagem) in Xavante Indians. Tissue Antigen 1993; 42:138–140.
6.
Niizeki H, Inoko H, Mizuki N, Inamoto N, Watanabe K, Hashimoto T, Nishikawa T: HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigen 1994;44: 248–251.
7.
Delgado JC, Yunis DE, Bozon, MV, Salazar M, Deulofeut D, Turbay D, Mehra NK, Pasricha JS, Raval RS, Patel B, Shah BK, Bhol K, Alper CA, Ahmed AR, Yunis EJ: MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigen 1996;48:668–672.
8.
Olerup O, Zetterquist H: HLA-DR typing by polymerase chain reaction amplification with sequence-specific primers (PCR-SSP); in Hui KM, Bidwell JL (eds): Handbook of HLA Typing Techniques. London, CRC Press, 1993, pp 149–173.
9.
Moraes ME, Fernandez-Vina M, Lazaro A, Diaz LA, Filho GH, Friedman H, Rivitti E, Aoki V, Stastny P, Moraes JR: An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue Antigen 1997;49:35–40.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.